Trulicity Alternatives: Dulaglutide Decision Guide (Mounjaro, Ozempic, Generics)

Trulicity is dulaglutide — Eli Lilly’s once-weekly GLP-1 receptor agonist, FDA-approved September 18, 2014 under BLA 125469 for glycemic control in adults with type 2 diabetes, and (since February 2020) for major adverse cardiovascular event (MACE) risk reduction in adults with T2D and established cardiovascular disease or multiple CV risk factors^[11]. Trulicity is not FDA-approved for chronic weight management. Patients seeking alternatives typically do so for one of four reasons: cost, supply or formulary, efficacy bump, or wanting a true weight-management indication. The alternatives map into four groups.

What Trulicity actually is (dulaglutide, T2D + CV risk reduction)

Trulicity is the brand name for dulaglutide injection, manufactured by Eli Lilly and Company. Dulaglutide is a long-acting Fc-fusion protein — two GLP-1 analogue peptides covalently linked to a modified human IgG4 Fc fragment, which extends the circulating half-life to about five days and supports once-weekly subcutaneous dosing. It is supplied as a single-dose autoinjector pen at 0.75 mg, 1.5 mg, 3.0 mg, and 4.5 mg per 0.5 mL^[10].

Trulicity has two FDA-approved indications^[10][11]:

• Type 2 diabetes glycemic control — original approval September 18, 2014 (BLA 125469).
• Cardiovascular risk reduction in T2D — supplemental approval February 21, 2020 (SUPPL 33), based on the REWIND trial^[1]. The label specifies adults with T2D who have established cardiovascular disease OR multiple cardiovascular risk factors.

Trulicity is not FDA-approved for chronic weight management. The largest dulaglutide weight-loss signal in any trial is the 4.5 mg dose in the AWARD-11 program (Frias 2021 Diabetes Care PMID 33397768)^[2] — mean weight loss of about 4.6 kg at 36 weeks in metformin-treated T2D adults, vs about 3.0 kg on the standard 1.5 mg dose. The AWARD-11 trial was designed for glycemic control, not chronic weight management; participants had T2D, not obesity as the entry criterion.

One regulatory wrinkle worth flagging: Trulicity is a biologic, regulated under the FDA’s Biologics License Application (BLA, 351(a)) pathway, not the small-molecule New Drug Application (NDA) pathway. Post-loss-of-exclusivity competition for Trulicity would come from biosimilars filed under the 351(k) pathway, not from small-molecule generics. As of mid-2026, no Trulicity biosimilar has been FDA-approved. Compare this to liraglutide (the small-molecule peptide in Victoza and Saxenda, regulated as a drug under the NDA pathway), which now has two FDA-approved generics — Hikma (December 2024) and Teva (August 2025)^[12].

Why patients seek Trulicity alternatives

Four reasons explain almost every Trulicity-alternative search query:

1. Cost. Trulicity has no generic or biosimilar; Lilly’s list price is high and patient cost-share is highly insurance-dependent. Patients seeking a cheaper GLP-1 with the same T2D indication look toward generic liraglutide (Hikma, December 2024) or other branded options on the formulary.
2. Supply or formulary access. When insurance step-therapy requires a different GLP-1 trial, or when a regional pharmacy lacks Trulicity stock, patients switch to whatever the formulary covers — usually Ozempic, Victoza, or generic liraglutide.
3. Efficacy bump. Mounjaro (tirzepatide) beat semaglutide head-to-head on HbA1c and weight in SURPASS-2^[3]. Patients with stubborn HbA1c on Trulicity 1.5 mg or 4.5 mg sometimes step up to Mounjaro via their endocrinologist for a stronger T2D drug.
4. Wanting a true weight-management indication. Patients with obesity comorbidity who want their GLP-1 to be labeled for chronic weight management (so insurance can cover it under the obesity benefit, not the diabetes benefit) need a chronic-weight-management drug — Wegovy, Zepbound, Saxenda, Teva generic liraglutide 3 mg, or Foundayo (the new oral option).

Group 1: In-class T2D upgrades — Mounjaro, Ozempic

If the patient’s primary indication is type 2 diabetes and the goal is a stronger T2D drug in the same therapeutic category, two named alternatives anchor the decision tree.

Mounjaro (tirzepatide)

Mounjaro is Eli Lilly’s dual GIP/GLP-1 receptor agonist for type 2 diabetes, FDA-approved May 2022. Unlike Trulicity and Ozempic (pure GLP-1 RAs), tirzepatide activates both the GLP-1 receptor and the GIP receptor — a dual-incretin mechanism associated with larger HbA1c reductions and larger weight-loss magnitudes in T2D trials.

The defining head-to-head trial is SURPASS-2 (Frías 2021 N Engl J Med PMID 34170647)^[3] — a 40-week randomized, open-label trial in 1,879 adults with type 2 diabetes comparing tirzepatide 5 mg, 10 mg, or 15 mg vs semaglutide 2 mg (the maximum Ozempic dose for T2D). Tirzepatide 15 mg delivered the largest HbA1c reduction (-2.30%) and the largest mean weight loss (-12.4 kg or about -13% body weight) at 40 weeks, vs semaglutide 2 mg (-1.86% HbA1c, -6.2 kg). SURPASS-2 did not include dulaglutide as a comparator, but cross-trial comparison vs AWARD-11 dulaglutide 4.5 mg (-4.6 kg)^[2] shows tirzepatide at the top of the in-class T2D weight-loss range.

Mounjaro is the right Trulicity alternative when: (1) HbA1c on Trulicity is inadequate, (2) the patient could benefit from larger weight loss alongside glycemic control, (3) the patient’s insurance will cover Mounjaro under the T2D benefit, and (4) the patient tolerates the GI side-effect ramp (tirzepatide’s nausea profile is broadly similar to semaglutide’s).

Ozempic (semaglutide)

Ozempic is Novo Nordisk’s once-weekly semaglutide for type 2 diabetes, FDA-approved December 2017. Semaglutide is a longer-half-life GLP-1 analogue (about 165 hours vs dulaglutide’s ~5 days), supporting once-weekly injection at doses of 0.5, 1.0, or 2.0 mg.

Ozempic’s cardiovascular outcomes anchor is SUSTAIN-6 (Marso 2016 N Engl J Med PMID 27633186)^[4] — a placebo-controlled trial of 3,297 adults with T2D and established CVD (or high CV risk) randomized to semaglutide 0.5 mg or 1.0 mg/week vs placebo. The primary 3-point MACE composite (CV death, nonfatal MI, nonfatal stroke) showed a hazard ratio of 0.74 (95% CI 0.58–0.95, p=0.02 for superiority), and the FDA added a cardiovascular risk-reduction indication to the Ozempic label in January 2020. Like REWIND for Trulicity^[1] and LEADER for Victoza^[5], SUSTAIN-6 is the trial that supports prescribing semaglutide in T2D patients with CVD for cardiovascular benefit.

Ozempic is the right Trulicity alternative when: (1) the patient prefers semaglutide-class pharmacology for any reason, (2) the formulary covers Ozempic but not Trulicity, (3) the patient wants slightly higher weight-loss magnitudes at the 2.0 mg dose than dulaglutide 1.5 mg delivers, and (4) the patient has T2D with established CVD (Ozempic’s SUSTAIN-6 indication aligns with Trulicity’s REWIND indication). Our Wegovy vs Ozempic evidence review walks through the semaglutide pharmacology in detail.

Group 2: Generic options — Hikma liraglutide, Amneal exenatide

Trulicity, Mounjaro, Ozempic, Wegovy, and Zepbound are all branded-only as of mid-2026 — no FDA-approved generics or biosimilars exist. The only GLP-1 receptor agonist molecule with FDA-approved generics is liraglutide.

Hikma generic liraglutide (T2D, references Victoza)

FDA application: ANDA 215503.
Approval date: December 23, 2024.
Sponsor: Hikma Pharmaceuticals USA Inc.
Indication: type 2 diabetes (mirrors the Victoza listed-drug label).
Significance: the first generic GLP-1 receptor agonist approved in the United States^[12]. Hikma liraglutide is bioequivalent to Victoza (TE code AP1), supplied as a 6 mg/mL multi-dose prefilled pen (18 mg / 3 mL).

Clinical positioning vs Trulicity: liraglutide is once-daily (vs Trulicity’s once-weekly), has a hard cardiovascular indication from the LEADER trial (Marso 2016 N Engl J Med PMID 27295427, hazard ratio 0.87 on 3-point MACE)^[5], and delivers about 2–3 kg mean weight loss at 26 weeks at the 1.8 mg/day dose in T2D — less than dulaglutide 4.5 mg, but the generic-cost pathway is real. For cost-sensitive T2D patients with established CVD on stable insurance, generic liraglutide is currently the cheapest pathway to a hard cardiovascular benefit in the GLP-1 class.

Teva generic liraglutide 3 mg (weight management, references Saxenda)

FDA application: ANDA 214568.
Approval date: August 27, 2025.
Sponsor: Teva Pharmaceuticals USA.
Indication: chronic weight management in adults with obesity or overweight plus a weight-related comorbidity, and pediatric obesity ages 12+ (mirrors the Saxenda listed-drug label)^[12]. This is the only generic GLP-1 RA approved for chronic weight management in the United States. It is liraglutide 6 mg/mL in the same multi-dose pen as Hikma’s product, but dosed up to 3.0 mg/day per the Saxenda label rather than 1.8 mg/day per the Victoza label.

Clinical positioning vs Trulicity: this option only applies if the patient has BMI ≥ 30 (or ≥ 27 with weight comorbidity) and the prescribing intent is chronic weight management rather than T2D glycemic control. Mean weight loss at the 3.0 mg dose is about 8.0% body weight at 56 weeks per the SCALE Obesity trial (Pi-Sunyer 2015 NEJM PMID 26132939)^[8] — meaningfully more than Trulicity 4.5 mg in T2D but meaningfully less than Wegovy or Zepbound.

Generic exenatide (Amneal) — no longer practically available

Byetta (exenatide twice-daily, FDA-approved 2005) and Bydureon BCise (exenatide extended-release, once-weekly, FDA-approved 2017) were the AstraZeneca GLP-1 RAs in the Trulicity-adjacent T2D market. Both were discontinued by AstraZeneca in October 2024 for commercial reasons (decreasing market share against Trulicity, Ozempic, and Mounjaro). Amneal had previously filed and received approval for generic exenatide, but the practical generic-exenatide pathway has shrunk significantly as the reference branded products exit the market. As of 2026, Amneal generic exenatide is not a meaningful alternative for new Trulicity prescriptions in primary care.

Group 3: Weight-management GLP-1s (if you qualify)

Patients with obesity comorbidity who want a true chronic-weight-management indication have five FDA-approved options in the GLP-1 class as of mid-2026. These drugs are not approved for type 2 diabetes (with the exception of Saxenda, which is approved for both indications at different doses), so the prescribing rationale is the patient’s weight-management indication, not their T2D.

Wegovy (semaglutide 2.4 mg, once weekly)

Novo Nordisk’s semaglutide for chronic weight management, FDA-approved June 4, 2021. The registrational trial is STEP-1 (Wilding 2021 N Engl J Med PMID 33567185)^[6] — 1,961 adults with obesity randomized to semaglutide 2.4 mg/week or placebo for 68 weeks. Mean weight loss with semaglutide was -14.9% body weight vs -2.4% on placebo. Wegovy added a cardiovascular indication in March 2024 based on the SELECT trial (in adults with overweight or obesity and established CVD, without T2D). See our Wegovy vs Ozempic evidence review for the side-by-side semaglutide comparison.

Zepbound (tirzepatide for obesity, once weekly)

Eli Lilly’s tirzepatide for chronic weight management, FDA-approved November 8, 2023 (same molecule as Mounjaro, different indication and dosing path). Registrational trial: SURMOUNT-1 (Jastreboff 2022 N Engl J Med PMID 35658024)^[7] — 2,539 adults with obesity randomized to tirzepatide 5/10/15 mg weekly vs placebo for 72 weeks. Mean weight loss at the 15 mg dose: -20.9% body weight, vs -3.1% on placebo. Zepbound currently delivers the largest mean weight loss of any FDA-approved GLP-1-class drug.

Saxenda + Teva generic liraglutide 3 mg (once daily)

Novo Nordisk’s Saxenda (liraglutide 3.0 mg/day, FDA-approved December 23, 2014) was the first GLP-1 RA approved for chronic weight management. SCALE Obesity (Pi-Sunyer 2015 NEJM PMID 26132939)^[8] showed about 8.0% mean body weight loss at 56 weeks. Saxenda is also FDA-approved for pediatric obesity ages 12+. The Teva generic referencing Saxenda^[12] was approved August 27, 2025 and is the only chronic-weight-management GLP-1 with a generic alternative.

Foundayo (orforglipron, oral, daily) — new in April 2026

Eli Lilly’s Foundayo (orforglipron) is the first oral, small-molecule, non-peptide GLP-1 receptor agonist — a true tablet, not a peptide pen injection. FDA-approved April 2026 for chronic weight management. The registrational trial ATTAIN-1 (Wharton 2025 NEJM PMID 40960239)^[9] randomized 3,127 adults with obesity to orforglipron 6/12/24/36 mg daily vs placebo for 72 weeks. Mean weight loss at the 36 mg dose: about -12.4% body weight. Foundayo’s magnitude sits between Wegovy and Zepbound but with the clinically meaningful advantage of oral dosing and no cold-chain refrigeration requirement. See our Foundayo overview for the dosing path, side effects, and how it slots into the obesity-medication landscape.

Group 4: Compounded — the regulatory caveat

Compounded semaglutide and compounded tirzepatide became widely available during the FDA-declared shortages of Ozempic and Mounjaro (2022–2024). The regulatory landscape changed substantially in late 2024 and early 2025:

• Tirzepatide shortage resolved: the FDA formally removed tirzepatide from its drug-shortage list in October 2024. This narrowed the legal pathway for 503A pharmacies and 503B outsourcing facilities to compound tirzepatide.
• Semaglutide shortage resolved: the FDA formally resolved the semaglutide shortage in February 2025. Same regulatory narrowing applies.
• Personalization carve-outs remain: patient-specific compounding for clinically documented intolerances, allergies, or dose-titration needs outside the commercial product’s strength options is still permitted under section 503A — but generic “alternative-to-Trulicity” compounded tirzepatide or semaglutide for general weight loss is now a tightly regulated grey area.

There is no compounded version of dulaglutide itself (Trulicity’s active ingredient). Dulaglutide is a complex Fc-fusion biologic and is not on any 503A or 503B compounding bulk-substances list. Patients looking at compounded semaglutide or tirzepatide as a Trulicity alternative should understand that they are switching active ingredient, not getting a generic of dulaglutide.

Is Trulicity being discontinued? (No — Bydureon was, Trulicity isn’t)

No. Trulicity remains FDA-approved and in active production by Eli Lilly as of 2026 (BLA 125469 ORIG-1, status AP; multiple recent supplemental approvals through 2025 confirm ongoing regulatory activity)^[11]. The Trulicity discontinuation rumor appears to be a conflation of two unrelated events:

• Bydureon BCise + Byetta discontinued: AstraZeneca discontinued both exenatide products in October 2024 for commercial reasons (declining market share). These are different drugs from different manufacturers in the same therapeutic class.
• Trulicity supply volatility 2022–2023: during the broader GLP-1 shortage period, Trulicity 0.75 mg and 1.5 mg autoinjector pens were intermittently on the FDA shortage list as demand spiked. The shortage resolved and Trulicity is now available at all standard dose strengths.

If you are reading a forum thread or social-media post claiming Trulicity is being discontinued in 2026, the claim is not supported by the FDA submission record or by Lilly’s commercial filings. Verify the source — the openFDA Drugs@FDA record for BLA 125469 is the authoritative reference^[11].

Side-by-side: dosing, cost, indication, efficacy magnitude

The dosing column shows the practical reason patients reach for a Trulicity alternative: once-weekly subcutaneous injection is the same convenience profile across Trulicity, Mounjaro, Ozempic, Wegovy, and Zepbound. Switching from Trulicity to any of the four weekly options preserves the dosing rhythm; switching to Victoza/Saxenda/Hikma/Teva liraglutide moves to daily injection; switching to Foundayo moves to daily oral dosing.

FAQ

Is Trulicity or Ozempic better for type 2 diabetes?

Both are FDA-approved for T2D plus cardiovascular risk reduction. Trulicity has the REWIND trial (HR 0.88 on 3-point MACE)^[1]; Ozempic has SUSTAIN-6 (HR 0.74 on 3-point MACE)^[4]. Cross-trial comparison favors semaglutide on weight loss and on HbA1c magnitude at the 2.0 mg dose, but the trials enrolled different populations and the comparison is not a head-to-head randomization. SURPASS-2 (tirzepatide vs semaglutide 2 mg) showed tirzepatide superior on both endpoints^[3]. The clinical decision depends on the patient’s CV risk profile, formulary access, and tolerability. This is a decision that should be made with a clinician.

Is Mounjaro better than Trulicity?

Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist; Trulicity (dulaglutide) is a pure GLP-1 receptor agonist. In the SURPASS-2 head-to-head (tirzepatide vs semaglutide 2 mg)^[3], tirzepatide 15 mg delivered larger HbA1c reductions (-2.30% vs -1.86%) and larger weight loss (-12.4 kg vs -6.2 kg) at 40 weeks. SURPASS-2 did not include dulaglutide, but the cross-trial comparison vs AWARD-11 dulaglutide 4.5 mg (-4.6 kg)^[2] shows tirzepatide with substantially larger weight and HbA1c effect sizes. For T2D patients who need stronger glycemic control or who could benefit from larger weight loss, Mounjaro is the more potent option.

What is the cheapest Trulicity alternative?

For type 2 diabetes glycemic control: Hikma generic liraglutide (FDA-approved December 23, 2024)^[12] is the first generic GLP-1 receptor agonist and is the cheapest in-class option in 2026. It is dosed once-daily (vs Trulicity once-weekly) and has a hard cardiovascular indication from the LEADER trial (HR 0.87 on 3-point MACE)^[5]. For chronic weight management: Teva generic liraglutide 3 mg^[12] is the only generic option but is meaningfully less potent than Wegovy or Zepbound. Cost varies widely by insurance coverage and pharmacy — talk to your pharmacist.

Can I use Trulicity for weight loss?

Trulicity is not FDA-approved for chronic weight management. Off-label, the AWARD-11 trial^[2]showed dulaglutide 4.5 mg produced about -4.6 kg mean weight loss at 36 weeks in metformin-treated T2D adults — meaningfully less than Wegovy (~14.9% body weight at 68 weeks in STEP-1)^[6] or Zepbound (~20.9% body weight at 72 weeks in SURMOUNT-1)^[7]. If chronic weight management is the goal, Wegovy, Zepbound, Saxenda, Teva generic liraglutide 3 mg, or Foundayo are the FDA-approved options. Our Trulicity weight-loss evidence review goes deeper on the off-label question.

Has Trulicity been discontinued in 2026?

No. Trulicity remains FDA-approved and on the US market in 2026 (BLA 125469 ORIG-1, status AP per Drugs@FDA)^[11]. Eli Lilly continues to manufacture Trulicity at all standard dose strengths (0.75 mg, 1.5 mg, 3.0 mg, 4.5 mg). The Trulicity discontinuation rumor is a misreading of AstraZeneca’s October 2024 discontinuation of Byetta and Bydureon BCise (exenatide, different drug, different manufacturer).

How do I switch from Trulicity to a different GLP-1?

Switching between GLP-1 receptor agonists requires a prescribing-clinician decision and a re-titration step (most GLP-1s start at a low dose and titrate up over 4–16 weeks to manage GI side effects). Direct dose equivalencies do not exist between Trulicity, Mounjaro, Ozempic, Wegovy, and Zepbound — the starting dose on the new drug follows that drug’s label, not your prior Trulicity dose. Our switching between GLP-1 medications guide walks through the practical considerations.

Is compounded semaglutide a legitimate Trulicity alternative?

The regulatory landscape changed in late 2024 and early 2025. The FDA resolved the tirzepatide shortage in October 2024 and the semaglutide shortage in February 2025, narrowing the legal pathway for 503A pharmacies and 503B outsourcing facilities to compound either active ingredient. Patient-specific compounding for documented clinical indications (allergies, dose-titration needs outside commercial strengths) remains permitted. General “alternative-to-Trulicity” compounded semaglutide or tirzepatide for routine weight management is now a tightly regulated grey area. There is no compounded version of dulaglutide itself.

Related research

• Trulicity (dulaglutide) for weight loss: FDA label and AWARD-11 evidence — the off-label weight-loss question covered in detail.
• Full GLP-1 medication reference list — every FDA-approved GLP-1 receptor agonist with DailyMed SetIDs and Drugs@FDA records.
• Victoza (liraglutide) evidence review — the daily-dosed GLP-1 with Hikma generic and LEADER cardiovascular benefit.
• Wegovy vs Ozempic evidence review — same molecule (semaglutide), different FDA approvals and doses.
• Wegovy alternatives for weight management — the obesity-indication decision tree.
• Foundayo (orforglipron) overview — the new oral GLP-1 RA, FDA-approved April 2026.
• GLP-1 pipeline: survodutide, maridebart, ecnoglutide — the next wave of injectable and oral GLP-1 alternatives in late-stage trials.